DekaBank Deutsche Girozentrale’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-86,100
| Closed | -$425K | – | 1428 |
|
|
2025
Q1 | $425K | Hold |
86,100
| – | – | ﹤0.01% | 998 |
|
|
2024
Q4 | $259K | Hold |
86,100
| – | – | ﹤0.01% | 1108 |
|
|
2024
Q3 | $455K | Hold |
86,100
| – | – | ﹤0.01% | 1033 |
|
|
2024
Q2 | $221K | Hold |
86,100
| – | – | ﹤0.01% | 1144 |
|
|
2024
Q1 | $420K | Hold |
86,100
| – | – | ﹤0.01% | 1036 |
|
|
2023
Q4 | $761K | Hold |
86,100
| – | – | ﹤0.01% | 957 |
|
|
2023
Q3 | $1.01M | Hold |
86,100
| – | – | ﹤0.01% | 876 |
|
|
2023
Q2 | $2.14M | Hold |
86,100
| – | – | ﹤0.01% | 734 |
|
|
2023
Q1 | $2.66M | Hold |
86,100
| – | – | 0.01% | 672 |
|
|
2022
Q4 | $1.6M | Hold |
86,100
| – | – | ﹤0.01% | 770 |
|
|
2022
Q3 | $2.21M | Hold |
86,100
| – | – | 0.01% | 687 |
|
|
2022
Q2 | $1.22M | Buy |
86,100
+60,000
| +230% | +$924K | ﹤0.01% | 828 |
|
|
2022
Q1 | $507K | Sell |
26,100
-2,100
| -7% | -$31.8K | ﹤0.01% | 1058 |
|
|
2021
Q4 | $468K | Sell |
28,200
-39,400
| -58% | -$657K | ﹤0.01% | 1114 |
|
|
2021
Q3 | $1.88M | Hold |
67,600
| – | – | 0.01% | 734 |
|
|
2021
Q2 | $1.97M | Hold |
67,600
| – | – | 0.01% | 729 |
|
|
2021
Q1 | $1.86M | Buy |
67,600
+4,500
| +7% | +$124K | 0.01% | 719 |
|
|
2020
Q4 | $1.71M | Buy |
63,100
+16,800
| +36% | +$435K | 0.01% | 703 |
|
|
2020
Q3 | $1.16M | Buy |
+46,300
| New | +$1.21M | 0.01% | 718 |
|
|
2019
Q4 | – | Sell |
-40,000
| Closed | -$550K | – | 1234 |
|
|
2019
Q3 | $550K | Sell |
40,000
-40,000
| -50% | -$489K | ﹤0.01% | 760 |
|
|
2019
Q2 | $1.01M | Buy |
+80,000
| New | +$1.01M | 0.01% | 785 |
|
|
2018
Q2 | – | Sell |
-28,200
| Closed | -$847K | – | 1249 |
|
|
2018
Q1 | $847K | Buy |
+28,200
| New | +$907K | 0.01% | 757 |
|
|
2016
Q2 | – | Sell |
-13,600
| Closed | -$239K | – | 1052 |
|
|
2016
Q1 | $239K | Sell |
13,600
-400
| -3% | -$8.14K | ﹤0.01% | 816 |
|
|
2015
Q4 | $497K | Buy |
14,000
+2,000
| +17% | +$69.3K | 0.01% | 701 |
|
|
2015
Q3 | $357K | Buy |
12,000
+500
| +4% | +$15.2K | ﹤0.01% | 755 |
|
|
2015
Q2 | $368K | Buy |
11,500
+400
| +4% | +$10.3K | ﹤0.01% | 766 |
|
|
2015
Q1 | $230K | Buy |
+11,100
| New | +$192K | ﹤0.01% | 871 |
|
DekaBank Deutsche Girozentrale's RVNC Position: Q2 2025 in Review
DekaBank Deutsche Girozentrale sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2025, closing a stake of 86,100 shares — an estimated $425K sold.
DekaBank Deutsche Girozentrale first reported a position in RVNC in Q1 2015 and held it in 27 quarters. The position peaked at $2.66M in Q1 2023. 0 funds tracked by Wall St. Rank hold RVNC as of Q2 2025.
- DekaBank Deutsche Girozentrale reported no remaining Revance Therapeutics, Inc. position as of Q2 2025 after selling out during the quarter.
- DekaBank Deutsche Girozentrale sold 86,100 Revance Therapeutics, Inc. shares in Q2 2025, an estimated $425K.
- DekaBank Deutsche Girozentrale first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 27 quarters.
- DekaBank Deutsche Girozentrale's Revance Therapeutics, Inc. position peaked at $2.66M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2025.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2025, filed 30 Jul 2025.